



2023 Bioshares Biotech Summit

Sander Bangma, CEO



DISCLAIMER

Introduction

The Company is at start-up stage with the objective of developing a medical technology business. The information provided in this Presentation is subject to a number of risks. The following is not intended to be an exhaustive list of the risk factors to which the Company is exposed.

Regulatory

Political, taxation, economic, legislative or regulatory change in Australia or in other countries where the Company intends to operate may have an adverse effect on the Company's investments and operations.

Industry

The industry in which the Company operates carries with it individual risks associated with that industry. It is not possible to detail all of the risk factors that the Company may be exposed to in respect of that industry, but may include factors related to legislation, trends in medical treatment and industry competition.

Timing

The timing of the necessary steps to commercialise the Company's business plan is dependent on many factors and accordingly the Directors can give no assurance as to the ultimate timing of such events.

Returns

Any outcomes and returns are dependent on the ultimate size and scale of the Company's potential business market, the information provided in this Presentation is an indication only and no guarantee on returns.

Economic conditions

General economic conditions, movements in interest and inflation rates and currency exchange rates may have an adverse effect on the Company's activities, as well as on its ability to fund those activities.

Patents


The medical technology developed by the Company may not be patentable, or where patents are sought, patents may not be secure. There is no guarantee that current or future patent applications will be successful. The inability to secure such patents could affect the value of the Company's technologies, adversely affecting the operations, financial position and performance of the Company.

Funding

As a biotechnology company investing in the development of its intellectual property, we don't anticipate product approval or any product revenue in the short term. Therefore we will continue to incur losses, not pay any dividends and we will need to raise additional funding in the future. There is no guarantee that additional funding in the future will be available or the price at which it could be raised.



Mosaic



NOVEL MEASURE OF
HIGH-RISK PLAQUE
ACTIVITY

PREDICTOR OF
2-3x INCREASED RISK
OF HEART ATTACK

**USE AI TO TRANSFORM ROUTINE CT SCANS INTO A
PERSONALISED ASSESSMENT OF YOUR HEART HEALTH**

Heart disease – a global challenge

Build up of fatty plaque in arteries



>9M

fatal heart attacks globally p.a.



>\$1T

cost of heart disease in the US by 2035

WE NEED BETTER RISK ASSESSMENT



>30%

of heart attacks in low-risk patients on CT



8x

expected increase in cardiac CT scans

WE NEED MORE AUTOMATED WORKFLOWS

WE NEED BETTER TREATMENT OPTIONS



30%

patients have another heart attack <2y



40%

shortfall of radiologists by 2027

Key unmet needs being solved by Mosaic



IMPROVED RISK ASSESSMENT
EARLY-STAGE DISEASE &
RESIDUAL RISKS

MORE COMPLETE PICTURE
BEYOND WHAT IS
CURRENTLY AVAILABLE

ABILITY TO PROCESS
THE INCREASED VOLUME
OF CT SCANS

Measures
high-risk
plaque activity

An icon of a heart with a white ECG line passing through it, symbolizing cardiovascular health and risk assessment.

Personalised
treatment &
improved health
outcomes

A simple white icon of a person standing with arms slightly out, representing individualized patient care.

Improved
AI assisted &
automated
workflows

An icon of a person's head and shoulders next to a list of three horizontal lines, representing AI-assisted workflows and automation.


**World-first
AI approach**

**revealing *invisible*
high-risk
plaque activity**

**using only
routine CT scans**




Mosaic is built on and validated with state-of-the-art imaging



**VALIDATED AGAINST
MICROSCOPIC RESOLUTION
IN VIVO IMAGING**

+



**HIGH-RISK PLAQUE ACTIVITY
MODEL DERIVED FROM
FUNCTIONAL IMAGING**



Patent pending (PCT, July 2022)
IP owned by Navier Medical

An Award-winning Innovation...



....underpinned by a decade of academic research



Business Model



Software as a Service



Highly scalable & always available



No new hardware / scanners needed



Significant margins / low COGS



Minimal user training



Multiple payment options possible
(e.g. pay-per-case, subscription models)



Reimbursement available

Our Value Proposition

PATIENTS & CLINICIANS



- ✓ Better risk assessment
- ✓ Personalised treatment plan
- ✓ Reduced re-admissions
- ✓ Improved patient outcomes

CLINICS & HOSPITALS



- ✓ Increased efficiency / revenue
- ✓ No hardware / CapEx needed
- ✓ Reimbursement codes in US
- ✓ Competitive advantage

Reimbursement codes (CPT) currently available

- ✓ CPT code for AI coronary plaque analysis (~US\$1,000) – 0625T
- ✓ CPT code for AI non-coronary plaque analysis (\$TBC) – 0710T
- ✓ CPT code for AI image analysis of stroke (~US\$1,000) – 0691T

SHAREHOLDERS




- ✓ High-potential company with large global market
- ✓ Early-stage with opportunity for high ROI
- ✓ IPO planned (2024+)
- ✓ ESIC status for tax offset



The Opportunity

8-fold increase in coronary CTA expected in coming years
2023 ~ 7M CCTA → 2030 ~ 55M CCTA



This does not include the market opportunity in stroke, aneurysm, peripheral arterial disease.....

The Competition

BENEFITS	NAVER	ELUCID	CARISTO	HEARTFLOW	ARTRYA	CLEERLY
HEART ATTACKS	✓	✓	✓	✓	✓	✓
STROKE & VASCULAR DISEASE	✓	✓				
MICROSCOPIC VALIDATION	✓	✓				
HIGH-RISK PLAQUE ACTIVITY	✓					

mosaic

- Validated against the state-of-the-art reference standards
- World 1st measures of early-stage disease and residual risks
- Predictor of 2-3x increased risk of heart attack

ASX companies active in medical imaging software



ASX: 4DX
Respiratory Imaging
(Mkt cap: ~ \$250M)



ASX: PME
Radiology Information Systems
(Mkt cap: ~ v\$6.8B)

Dreisbach et al. Heart 2018;104:921-7 and Frost & Sullivan market report
\$585 is 50% of the average cost of a HeartFlow, Cleerly and Caristo analysis – no costs available for others

Product Roadmap



2023



mosaic core

- FDA pre-submission meeting (**June**)
- Positive meeting, pathway confirmed
- 510(k) submission (**Q4 CY23**)
- 510(k) clearance anticipated (**H1 CY24**)



mosaic cloud

- AI prototype developed
- Predicate identified, pathway confirmed
- FDA 510(k) submission

2024+




mosaic+

- Plaque activity prototype developed
- Initial feedback from FDA
- Further development

...more product concepts under development

Key upcoming milestones



OPEN TO OPPORTUNITIES

- Collaborate with radiology clinics
- Studies with KOL cardiologists
- Additional funding streams

IPO

ASX ticker reserved
NMX

Assumes favourable market conditions



Leadership & Management



Otto Buttula
Chairman

- Extensive experience and success in investment, funds management and Info/Bio/Med-Tech
- Built and grew IWL Ltd (ASX: IWL) prior to takeover by CommBank (ASX: CBA)
- Director/Chair in several ASX listed biotech companies



Sander Bangma
CEO

- Over 12 yrs experience in medical software, including obtaining FDA, TGA & CE
- Led ASX listed software company Resonance Health Ltd (ASX:RHT) as GM & COO
- Led product strategy & development of 300M+ users global software platform
- MBA, MSc in Computer Science



Barry Doyle
Founder & CTO

- International profile in cardiovascular bioengineering with >18 yrs experience
- Program Head of Cardiovascular Science (until 2022) & Head of Vascular Eng. Lab at the Harry Perkins Institute
- Adj. A/Professor of Biomedical Eng. at University of Western Australia (UWA)
- BEng (Biomedical), PhD, FIEAust, GAICD



Lachlan Kelsey
Head of Engineering

- Co-developed methods behind Navier Medical during his PhD at UWA / Perkins (with Barry Doyle)
- PhD in Cardiovascular Biomechanics and BEng in Mechanical Engineering



Bronte Maddock
QA & Reg Manager

- Experienced compliance, regulatory affairs & risk management professional
- Comprehensive understanding of Medical Device ISO standards & regulations, including FDA, TGA and EU



Navier Medical Ltd

ACN 651 654 858

Contact

Sander Bangma - CEO

E sander.bangma@naviermedical.com

M +61 422 798 011

ESIC: tax incentive for early stage investors



Navier Medical Ltd qualifies as an Early-Stage Innovation Company (ESIC).

Investors into qualifying ESIC entities receive tax benefits depending on their individual tax and investment situation. *All investors should seek their own tax advice to determine tax impact.*

The tax benefits include:

- 20% non-refundable carry forward tax offset of the amount paid for their qualifying investments, capped at \$200,000 each income year for Corps Act “Sophisticated Investors”;
- modified capital gains tax treatment for equity interests held more than 12 months and less than 10 years, whereby there is no CGT on disposal;
- investors who are not Corps Act “Sophisticated Investors” limited to \$50,000 investment or lose all ESIC benefits.